Biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) disclosed on Monday that the US Food and Drug Administration has accepted its supplemental New Drug Application for ARIKAYCE (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial regimen. The FDA granted Priority Review and set a PDUFA target action date of 28 January 2027.
The application seeks full approval of ARIKAYCE, which received accelerated approval in 2018 for refractory MAC lung disease. It is supported by the Phase 3b ENCORE study, conducted to fulfil the post-marketing requirement associated with the accelerated approval.
ENCORE met its primary endpoint and multiplicity-controlled secondary culture conversion endpoints, with ARIKAYCE plus multidrug therapy producing statistically significant improvements in respiratory symptoms and culture conversion compared with multidrug therapy alone. The 425-patient study also showed earlier, greater and more durable culture conversion, with no new safety signals.
Insmed plans to review the ENCORE results with Japan's Pharmaceuticals and Medical Devices Agency in Q4 2026 to support a potential label expansion in Japan.
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201